Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord. SE CONNECTER À UN COMPTE LECTEUR CRÉER UN COMPTE LECTEUR
Monthly information on share capital and company voting rights
15 mars 2023 17h02 HE
|
Cellectis Inc.
NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting
14 mars 2023 17h00 HE
|
Cellectis Inc.
NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Autolus Therapeutics Has No Business Relationship with Silicon Valley Bank
13 mars 2023 07h00 HE
|
Autolus Therapeutics plc
LONDON, March 13, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today and...
T-cell Therapy Global Market Report 2023: Rising Global Investments in Gene and Cell Therapy Arena Presents Opportunities
13 mars 2023 05h18 HE
|
Research and Markets
Dublin, March 13, 2023 (GLOBE NEWSWIRE) -- The "T-cell Therapy Market Size, Share & Trends Analysis Report By Modality, By Therapy (CAR T-cell, Tumor-Infiltrating Lymphocytes), By Indication...
Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
08 mars 2023 16h45 HE
|
Cellectis Inc.
Entered into a €40 million credit facility with the European Investment Bank and closed an approximatively $25 million follow-on equity offering to support Cellectis’ research, development and...
Autolus Therapeutics Reports Full Year 2022 Financial Results and Operational Progress
07 mars 2023 07h00 HE
|
Autolus Therapeutics plc
Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) B-cell Acute Lymphoblastic Leukemia (ALL) met the primary endpoint in the pivotal Phase 2 FELIX study and is on track...
Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update
06 mars 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, March 06, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop...
Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023
01 mars 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop...
Autolus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 7, 2023
15 févr. 2023 07h00 HE
|
Autolus Therapeutics plc
LONDON, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Monthly information on share capital and company voting rights
09 févr. 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...